

Application number

1980471

Registration number

TMA1254464

Type(s)

Design

Category

Trademark

CIPO Status

REGISTERED

TM5 statusLIVE/REGISTRATION/Issued
and ActiveThe trademark application has
been registered with the Office.**Filed**

2019-08-14

Registered

2024-09-09

Registration Expiry Date

2034-09-09

Registered OwnerTeva Pharmaceutical
Industries Ltd.
124 Dvora HaNevi'a
6944020 Tel Aviv-Jaffa
ISRAEL**Agent**OSLER, HOSKIN &
HARCOURT LLP
Suite 320, World Exchange
Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9**Documents**[View documents](#)**Index headings**TEVA
V**Vienna information (Code & Description)**

5.3.11	Other leaves
A 5.3.13	Stylized leaves
A 5.3.15	Two to four leaves
26.1.1	Circles
26.1.4	Two circles, two ellipses, one inside the other
26.1.5	More than two circles or ellipses, inside one another, spirals
26.1.6	Several circles or ellipses, juxtaposed, tangential or intersecting
A 26.1.24	Circles or ellipses with dark surfaces or parts of surfaces
26.4.2	Rectangles
A 26.4.5	One quadrilateral
26.4.10	Quadrilaterals containing one or more circles, ellipses or polygons
26.4.12	Quadrilaterals containing one or more other geometrical figures -- Note: Including quadrilaterals containing bent or straight lines (except 26.4.11).
A 26.4.15	Quadrilaterals containing representations of animals or parts of animals' bodies or plants
A 26.4.18	Quadrilaterals containing one or more letters
26.7.4	Circles or ellipses with lines (except 26.7.3)
26.11.2	Two lines or bands
A 26.11.6	Thick lines, bands
A 26.11.9	Oblique lines or bands
A 26.11.12	Curved lines or bands (except a 26.11.13)
26.15.1	Spheres
27.3.1	Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object
A 27.3.11	Letters or numerals representing a plant

Goods (Nice class & Statement)

5	(1) Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and
---	---

treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations for human use; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations for the treatment of circulatory system diseases and disorders; Pharmaceutical preparations for the treatment of sensory organ disorders; Pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for the treatment of peripheral nervous system disorders; Pharmaceutical preparations for the treatment of neurological disorders.

Recordals (known also as Footnotes)

Owner Address Change / Changement d'adresse du propriétaire

DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2022-02-28

COMMENTS / COMMENTAIRES: Voir Preuve au dossier/See evidence on File No. 2121983

Action History

Action	Action date	Due date	Comments
Filed	2019-08-14		
Created	2019-08-15		
Formalized	2019-08-19		
Amendment to Application	2022-02-28		Owner Address Change / Voir Preuve au dossier/See evidence on File No. 2121983
Pre-Assessment Letter			

Sent	2022-04-12		Retired Goods or Services
Search Recorded	2024-05-10		
Examiner's First Report	2024-05-10	2024-11-10	
Approved	2024-05-27		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2024-05-27		APPROVED BY PROGRAM EX200M1
Advertised	2024-06-19		Vol.71 Issue 3634
Registration Pending	2024-09-09		
Registered	2024-09-09	2034-09-09	